Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 305

Results For "AI"

9355 News Found

Merck launches AAW workstation to advance lab automation
News | July 15, 2025

Merck launches AAW workstation to advance lab automation

New platform powered by Opentrons expands lab automation to accelerate scientific discovery


Sun Pharma launches LEQSELVI in US for treatment of severe alopecia areata
News | July 14, 2025

Sun Pharma launches LEQSELVI in US for treatment of severe alopecia areata

LEQSELVI now available for prescription in U.S. nationwide, offering a new option for eligible patients


AstraZeneca's Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial
Clinical Trials | July 14, 2025

AstraZeneca's Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial

Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo


Merck to initiate Phase 3 trials for investigational once-monthly HIV prevention pill
News | July 14, 2025

Merck to initiate Phase 3 trials for investigational once-monthly HIV prevention pill

In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally


Moderna receives USFDA approval for Covid-19 vaccine ‘Spikevax’
Drug Approval | July 13, 2025

Moderna receives USFDA approval for Covid-19 vaccine ‘Spikevax’

Spikevax is now approved for all individuals aged 6 months through 64 years at increased risk for COVID-19 disease


Briefs: Emcure Pharmaceuticals and Gland Pharma
News | July 12, 2025

Briefs: Emcure Pharmaceuticals and Gland Pharma

Emcure Pharmaceuticals successfully completes USFDA PAI of Oncology facility


Indegene launches NEXT Medical Writing Automation
News | July 12, 2025

Indegene launches NEXT Medical Writing Automation

To streamline complex medical writing workflows with GenAI


Panacea Biotec reaches settlement with Apotex
News | July 12, 2025

Panacea Biotec reaches settlement with Apotex

Apotex will also pay US$ 2.5 million upon receipt of final USFDA approval of the ANDA that is the subject of the Collaboration Agreement for Paclitaxel Protein-Bound Particles for Injectable Suspension